Litcius/Paper detail

Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study

Mazyar Shadman, Ian W. Flinn, Moshe Levy, Ryan Porter, John M. Burke, Syed F. Zafar, Jamal Misleh, Edwin Kingsley, Habte Yimer, Benjamin G. Freeman, Subramanya S Rao, Arvind Chaudhry, Praveen K. Tumula, Mitul Gandhi, Sudhir Manda, Dih-Yih Chen, Kunthel By, Linlin Xu, Ye Liu, Rocco J. Crescenzo, Adam Idoine, Xiaoping Zhang, Aileen Cohen, Jane Huang, Jeff P. Sharman

2022The Lancet Haematology89 citationsDOI

Topics & Concepts

IbrutinibMedicineMantle cell lymphomaInternal medicineAdverse effectClinical endpointBruton's tyrosine kinaseProgressive diseaseOncologyPhases of clinical researchLymphomaChronic lymphocytic leukemiaChemotherapyTyrosine kinaseClinical trialLeukemiaReceptorChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentPhagocytosis and Immune Regulation